Command Palette

Search for a command to run...

ORCHPHARMA

734.4-1.50%
Market Cap
₹3,776.80 Cr
Stock P/E
44.32
ROCE
8.05%
ROE
7.86%
Book Value
₹252.57

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Others

From Last Concall

POSITIVES
  • Q4 and full-year 2024-25 results show meaningful growth in sales and EBITDA.
  • Management maintains a positive medium-term trajectory despite near-term headwinds, including a merger integration path.
NEGATIVES
  • Near-term profitability pressures persist due to AMS division drag and pricing dynamics.
  • Capex-driven 7-ACA project is experiencing execution delays, potentially pushing commercialization timelines.

Peers Summary

Sector Leader

Orchid Pharma Ltd. demonstrates strong growth metrics compared to its peers, particularly in revenue growth and EPS. However, it has a relatively high PE ratio, indicating potential overvaluation concerns. Companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. stand out for their strong profitability and attractive valuations, making them potential value picks. Overall, Orchid Pharma has a competitive edge in growth but needs to address valuation concerns.

Key Points
  • Orchid Pharma shows robust revenue growth (YoY) at 23.05%.
  • Cipla and Dr. Reddy's are the most attractive based on profitability and valuation.
  • Divi's Laboratories has the highest PE and is considered overvalued.
  • Mankind Pharma has impressive growth metrics but is not as profitable as peers.
Top Performers
Cipla Ltd.

Strong profitability metrics and attractive valuation (PE 23.73).

Dr. Reddy's Laboratories Ltd.

Top ROE and ROCE with excellent growth trajectory and low PE (15.50).

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.